Faculty Opinions recommendation of Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

2009 ◽  
Author(s):  
Florence Duffaud
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Imatinib Mesylate ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor ◽  
Adjuvant Imatinib ◽  
Early Results

scholarly journals Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate

2020 ◽  
Vol 26 (6) ◽  
Author(s):  
Hal A Lewis ◽  
David Y Chen ◽  
Ilana S Rosman ◽  
Joel Picus ◽  
Milan J Anadkat
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Imatinib Mesylate ◽  
Stromal Tumor ◽  
Pemphigus Foliaceus ◽  
Adjuvant Imatinib

Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10015-10015 ◽  
Author(s):  
T. Nishida ◽  
A. Sawaki ◽  
T. Doi ◽  
Y. Yamada ◽  
Y. Komatsu ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

Oncotarget ◽  
2017 ◽  
Vol 8 (27) ◽  
pp. 44121-44130 ◽  
Author(s):  
Chun-Nan Yeh ◽  
Ming-Huang Chen ◽  
Yen-Yang Chen ◽  
Ching-Yao Yang ◽  
Chueh-Chuan Yen ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Stromal Tumor
Sign in / Sign up

Export Citation Format

Share Document